2nd Ann Arbor Cell Therapy and **Transplantation Symposium**

Monday, February 18, 2019 8:00 am – 3:00 pm

University of Michigan Hospital **Danto Auditorium** 1500 E. Medical Center Dr. Ann Arbor, MI 48109

Target Audience:

This symposium is intended for physicians, physician assistants, nurse practitioners, and other healthcare professionals involved in Hematology/Oncology, Cellular Immunotherapies and those who provide follow-up care for patients with leukemia, lymphoma, myeloma and other hematological diseases after transplantation.

Program Objectives:

Our goal for this conference is to provide participants with an understanding of:

- Advances being made in Blood and Marrow Transplantation; •
- The use of cellular immunotherapies now and what is on the horizon;
- How to decide between new therapies and standard transplantation; and •
- Addressing refractory cancers and treatment options. •

Agenda

8:00 – 8:30	Welcome and Breakfast John Magenau, MD	11:30 – 12:30 Lu	
	Assistant Professor of Internal Medicine, University of Michigan Medical Director, Adult BMT	12:30 – 1:10	Alt No Ma Sr.
8:30 – 9:10	Measuring Microbiome Transmission in HCT Ami Bhatt, MD		Pr
	Assistant Professor of Medicine and Genetics, Stanford University	1:10 – 1:50	Ge Be Bri
9:10 — 9:50	Novel Strategies to Activate NK Cells to Treat Cancer Jeffrey Miller, MD <i>Professor of Medicine, University of Minnesota</i>		As Un
9:50 – 10:10		2:00 - 2:15	Clo Jo
10:10 – 10:5	0 Novel Insights in GVHD Target Tissue Injury Takanori Teshima, MD, PhD <i>Professor of Medicine in the Division of Hematology</i>		As Un Me
	and Deputy-director, Hokkaido University Hospital	2:15 – 3:00	To
10:50 – 11:3	0 ST2 as Biomarkers and in Immunotherapies Sophie Paczesny, MD, PhD <i>Nora Letzter Professor of Pediatrics,</i>	3:00	Ad

Indiana University School of Medicine

nch

ternative Donor Transplants: Malignant and on-Malignant Diseases ary Eapen, MBBS, MRCPI, MS Scientific Director – Research Operations ofessor of Medicine, Medical College of Wisconsin

- nomic MRD Monitoring of Myeloid Malignancies fore and After Transplantation ian Parkin, MD sistant Professor of Internal Medicine, niversity of Michigan
- osing Remarks hn Magenau, MD ssistant Professor of Internal Medicine, niversity of Michigan edical Director, Adult BMT
- ur of Lab and BMT Clinic (optional)
- journ



RSVP by February 11 at http://michmed.org/EOPg2